database > company
TolerRX
Biotech Specialty Pharma
300 Technology Square, 3rd Floor
Cambridge, MA 02139 USA
phone:617-354-8100
fax:617-354-8300
Symbol private
Founded 2000
Employees
          www.tolerrx.com
Research Sector Biotech Specialty Pharma
Summary Description
Technologies that induce or remove immunological tolerance.
Management
Douglas J. Ringler, V.M.D., Co-Founder, President & Chief Executive Officer; Herman Waldmann , Ph.D., FRCPath, MRCP, FRS, FMedSci, Co-Founder, Chairman, Scientific Advisory Board; Louis Vaickus, M.D., Chief Medical Officer; Thomas A. Shea, M.B.A., Chief Financial Officer
Keywords
cancer, monoclonal antibodies, Diabetes, blood sugar, diabetic, metabolic, insulin, immune system, psoriatic arthritis, autoimmune disease

Comment | Printable Version | Modify profile Jan. 15, 2009

Description
TolerRx specializes in the discovery and development of therapies that induce or remove immunological tolerance. The Company's therapies are designed to reprogram the immune system and provide a stable effect after a short course of therapy. TolerRX has five monoclonal antibodies in its development pipelines, including two humanized antibodies that are in clinical trials. Its TolerMab antibody technology enables the modification of antibodies to induce immunological tolerance. The Company also has ongoing research and development programs focused on generating new monoclonal antibody and small molecule products for the treatment of immunological diseases.
Products / Services
TolerRX's TRX4 is a humanized monoclonal antibody that binds to a receptor found on all T-cells called CD3, which is involved in normal T-cell signaling. TRX4 is designed to block the function of T-effector cells that attack the body and cause autoimmune disease. TRX4 is currently being studied in a Phase II clinical trial for new-onset Type I diabetes. The company is also involved in evaluating four other autoimmune products.
Technology / Differentiation
T cells are at the heart of most immune responses. TolerRX has focused its research on T-regulatory cells which can actively suppress the generation and function of T-effector cells. T-regulatory cells are among the most powerful mechanisms used by the body to establish and maintain immunological tolerance. TolerRX believes that T-regulatory cells provide novel mechanisms and targets for use in the development of products to treat diseases of immune system.


2010-09-01-375